SCMOM 2012_Regen BioPharma, Inc.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology